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Abstract 
To evaluate the contribution of 18F-dihydroxyphenylalanine (DOPA) PET in association with conventional MRI 
in predicting treatment response and survival outcome of pediatric patients with diffuse intrinsic pontine 
gliomas (DIPGs). 
Methods: We retrospectively analyzed 19 children with newly diagnosed DIPGs who underwent 18F-DOPA 
PET/CT and conventional MRI within one week of each other at admission and subsequent MRI follow-up. 
Following co-registration and fusion of PET and MRI, 18F-DOPA uptake avidity and extent (PET tumor volume 
and uniformity) at admission, along with MRI indices including presence of ring contrast-enhancement, tumor 
volume at admission and at maximum response following first-line treatment, were evaluated and correlated 
with overall survival (OS). The association between 18F-DOPA uptake tumor volume at admission and MRI 
tumor volume following treatment was evaluated. Statistics included Wilcoxon signed-rank and Mann-Whitney 
U tests, Kaplan-Meier OS curve and Cox analysis. 
Results: DIPGs with a 18F-DOPA uptake Tumor/Striatum (T/S) ratio >1 presented an OS ≤ 12 months and 
lower degree of tumor volume reduction following treatment (p = 0.001). On multivariate analysis, T/S (p = 
0.001), ring enhancement (p = 0.01) and the degree of MRI tumor volume reduction (p = 0.01) independently 
correlated with OS. In all patients, areas of increased 18F-DOPA uptake overlapped with regions demonstrating 
more prominent residual components/lack of response following treatment. 
Conclusions: 18F-DOPA PET provides useful information for evaluating the metabolism of DIPGs. T/S ratio is 
an independent predictor of outcome. 18F-DOPA uptake extent delineates tumoral regions with a more 
aggressive biological behaviour, less sensitive to first line treatment. 
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Introduction 
In pediatric patients, diffuse intrinsic pontine 
glioma (DIPG) represents the most difficult brain 
tumor to treat and the leading cause of brain 
tumor-related death [1,2]. 
Despite recent remarkable genomic discoveries, 
partially included in the revised 2016 WHO 
classification, such as highly recurrent H3K27M 









progress in the management of DIPG. Radiotherapy 
(RT) remains the current standard of care, providing 
transient clinical improvement and a limited survival 
benefit. Tumor progression is almost universal, with 
median overall survival less than 1 year [4]. Several 
clinical trials over the last few decades have also 
investigated different adjuvant chemotherapies 
(ChT), albeit without significant survival benefit [4-6]. 
Routine biopsy in DIPG remains under debate [7] 
since the diagnosis may be established with imaging 
alone [8]. 
Several prior imaging studies focusing on 
conventional and/or advanced MRI modalities have 
attempted to identify non-invasive parameters able to 
predict survival at the time of diagnosis with not 
univocal results, most requiring further investigations 
in large DIPG clinical trials [9-14]. 
Additional non-invasive biomarkers that could 
predict disease evolution are still awaited to 
contribute to the establishment of well-timed, 
personalized and more effective therapies, aiming to 
improve overall survival and quality of life of DIPG 
patients. 
Positron Emission Tomography (PET) imaging 
with amino-acid tracers, such as 18F-dihydroxy-
phenylalanine (DOPA), is a diagnostic tool able to 
provide non-invasive information of brain tumors. 
18F-DOPA uptake has been demonstrated to correlate 
with aggressiveness of diffusely infiltrating pediatric 
gliomas [15-17] and with H3K27M mutational status, 
independently of histology [18]. The activity of 
18F-DOPA PET seems both based on and strictly 
correlated to tumor metabolism, which is associated 
with enhanced and altered channeling of amino-acids 
for protein synthesis and cell division in pediatric 
high-grade infiltrative astrocytomas [19]. No prior 
studies have so far evaluated metabolic information 
obtained by 18F-DOPA PET focusing on DIPGs. 
On the basis of these considerations, the overall 
objective of this retrospective study was to analyze 
diagnostic and prognostic information obtained by 
18F-DOPA PET in a group of children with newly 
diagnosed DIPGs. Specifically, we aimed to evaluate 
the contribution of the 18F-DOPA PET delineated 
tumor volume at diagnosis to conventional MRI based 
tumor volume at diagnosis and at maximum response 
following first line ChT-RT treatment, and to correlate 
18F-DOPA PET and MRI indices with outcome in 
terms of overall survival (OS). 
Methods 
Patient population 
We retrospectively evaluated all consecutive 
pediatric patients (aged less than 18 years at 
diagnosis) referred at IRCCS Istituto Giannina 
Gaslini, Genoa, Italy between 2012 and 2019 for newly 
diagnosed treatment naïve DIPGs (T1 hypointense 
and T2 hyperintense diffusely infiltrating lesion 
arising and involving ≥ 50% of the pons) who 
underwent conventional MRI and 18F-DOPA PET at 
admission, and subsequent post-treatment MRI 
follow-up. 
Nineteen (12 females and 7 males) subjects were 
identified. Patient age ranged from 3 to 10 years 
(median, 7 years). Six of these patients had been 
previously included in a retrospective study aimed to 
evaluate the diagnostic ability of 18F-DOPA PET and 
advanced MRI techniques in discriminating H3K27M- 
mutant from wild-type pediatric diffuse midline 
gliomas [18]. 
Clinical information reviewed for each subject 
included the time of diagnosis and treatment onset, 
OS (defined as the interval from treatment initiation 
to death from any cause), and treatments received. 
Because OS is regarded as the most reliable outcome 
variable for DIPG, progression-free survival was not 
evaluated [6]. 
Regarding treatment, all patients underwent 
first-line treatment with combined chemotherapy/ 
immunotherapy (Vinorelbine and Nimotuzumab) 
and radiotherapy. Irradiation was performed in all 
patients using conventional fractionation (1.8 Gy per 
day) to a total dose of 54 Gy. In case of local 
progressive disease or progression with 
dissemination, re-irradiation was performed with 
variable doses and schedule according to disease sites 
(12 subjects underwent re-irradiation). 
Ten patients underwent biopsy at diagnosis 
(following 18F-DOPA PET and MRI) with histological 
and molecular characterization. In particular, 
molecular analyses were performed to test the 
presence of mutations in the histone variants H3.3 
(H3F3A) and H3.1 (HIST1H3B). Among subjects who 
underwent histological and molecular 
characterization, there were 2 patients with H3K27M 
wild-type (1 histologically defined diffuse 
astrocytoma and 1 anaplastic astrocytoma) and 8 with 
H3K27M-mutant lesions (4 histologically defined 
anaplastic astrocytomas and 4 glioblastomas). All 
subjects with H3K27M-mutant DIPGs presented 
mutations in the histone variant H3.3 (H3F3A). 
Surveillance was performed with regular clinical 
and MRI follow-up. The Regional Ethics committee of 
Liguria, Genoa, Italy, approved the retrospective data 
evaluation. 
Image protocol and analysis 
Because the study spanned 7 years, MRI 
examinations were performed on 1.5T (14 patients; 





Intera Achieva; Philips, Best, the Netherlands) and 3T 
(5 patients; Ingenia Cx, Philips, Best, the Netherlands) 
scanners. 
All patients underwent routine clinical MRI 
examinations including axial fluid attenuation 
inversion recovery (FLAIR), T2-weighted images, and 
pre- and post-contrast (0.1 mmol/kg, macrocyclic 
ionic agent) T1-weighted images. 
18F-DOPA PET/CT was carried out at admission 
within one week of baseline MRI. Imaging studies 
were performed within 2 weeks before treatment 
initiation; subsequent evaluations were performed 
with MRI at 4-5 weeks after RT completion and then 
every 12-13 weeks, unless new symptoms occurred. In 
case of suspected pseudo-progression at first post- 
treatment MRI evaluation, additional close MRI 
follow-up at 4-5 weeks was performed (2 patients). 
18F-DOPA PET studies were executed with a 
PET/CT Discovery ST system (GE Healthcare, 
Milwaukee, WI, USA), as previously described 
[17,18]. Data were acquired in 3-dimensional mode, 20 
minutes after 18F-DOPA administration (median 
injected activity of 100 MBq, range 70-120 MBq 
according to body weight) with a scanning time of 30 
minutes. Patients fasted for at least 4 hours before 
18F-DOPA administration (IASOdopa®, IASON 
Labormedizine Ges. Mbh & Co. KG, Graz-Seiersberg, 
Austria). Carbidopa premedication was not utilized. 
A non-diagnostic low dose CT scan (120 kV, 80 mA, 
0.6 s per rotation) was used for attenuation correction. 
Images were first analysed on a dedicated 
workstation (Xeleris, GE Corporation), also allowing 
semiautomatic co-registration and fusion of 18F-DOPA 
PET and MR images to ensure precise anatomical 
comparability. Using dedicated software developed 
for research purposes (Quanta Oncology, Camelot 
Biomedical Systems, Genoa, Italy) we performed 
volumetric tumor analysis on axial 18F-DOPA PET 
and MRI FLAIR images. In detail, the anatomic tumor 
extent was delineated on MRI FLAIR images [20] 
using a perimeter technique with user-assisted 
semi-automated software; 18F-DOPA PET tumor 
volume was delineated based on 18F-DOPA uptake 
avidity (tumoral areas with increased uptake 
compared to normal background reference region). 
For each case tumor volume delineation was 
reviewed in consensus by a nuclear medicine 
physician and a neuroradiologist with 17 and 15 years 
of experience (A.P. and G.M.). Volume of interests 
(VOIs) were generated and 18F-DOPA PET and MRI 
tumor volume at admission were then recorded. The 
same procedure was performed following first-line 
treatment with ChT-RT on the MRI studies 
demonstrating the maximum degree of response (in 
all but two subjects the first MRI evaluation following 
ChT-RT was selected). MRI tumor volume following 
treatment and the corresponding tumor volume 
change since admission, were recorded. 
For each patient, 18F-DOPA uniformity, defined 
as the percentage of the MRI tumor volume at 
admission (as delineated on FLAIR images) 
demonstrating increased 18F-DOPA PET uptake, was 
also calculated [21,22]. 
PET tumor volume was delineated on 18F-DOPA 
PET studies by including all voxels with standardized 
uptake value (SUV) above the maximum (max) SUV 
of the normal background reference tissue. For the 
normal (N) background reference tissue, a VOI 
(diameter 20 mm) was drawn in the normal cerebral 
hemisphere at the level of the left centrum semiovale, 
including cortical and white matter. For each case, the 
radiotracer concentration in the tumoral VOI was 
normalized to the injected dose per patient body 
weight, and the SUV max was obtained for each lesion 
[maximum pixel value (kBq/mL) within the VOI/ 
injected dose (kBq)/patient weight (g)]. An additional 
VOI was drawn over the left striatum including the 
entire putamen (S). Ratios of tumor to normal tissue 
uptake were also generated by dividing the tumor 
SUVmax by the SUVmax of the striatum (T/S) [17,18]. 
In case of absence of increased 18F-DOPA uptake, a 
VOI including the tumor on MRI FLAIR images was 
delineated on co-registered 18F-DOPA PET images to 
generate T/S and T/N ratios. 
Three main tumor uptake patterns were defined: 
(i) absence of increased 18F-DOPA uptake, 
characterized by a tumor uptake not exceeding the 
uptake of the normal background reference tissue 
(T/N ≤ 1) and lower uptake than striatum (T/S < 1); 
(ii) mildly/moderately increased 18F-DOPA uptake, 
characterized by a tumor uptake exceeding the uptake 
of the normal background reference tissue but 
remaining lower than or equal to that of the striatum 
(T/N > 1 and T/S ≤ 1); and (iii) markedly increased 
18F-DOPA uptake, in which tumor uptake clearly 
exceeded that observed in the normal background 
reference tissue and striatum (T/N > 1 and T/S > 1) 
[23]. 
For each patient we also evaluated the 
association between baseline 18F-DOPA PET avidity 
and MRI based tumor volume at maximum response 
by delineating VOIs and assessing the overlap of the 
residual MRI tumor volume and initial 18F-DOPA PET 
volume [22]. 
Presence or absence of areas of ring-shaped 
enhancement on post-contrast T1-weighted images 
was also recorded. Distribution of areas of 
ring-shaped enhancement in relation to areas of 
increased 18F-DOPA uptake was also evaluated on 
baseline MRI studies. 






Each patient was risk stratified according to age, 
sex, H3K27M mutation, presence or absence of ring- 
shaped enhancement on MRI, pre- and post-treatment 
MRI tumor volume, 18F-DOPA uptake avidity (T/S), 
pre-treatment PET tumor volume and pre-treatment 
PET uniformity. 
Statistical analysis 
Descriptive statistics included mean, standard 
deviation, minimum, and maximum of continuous 
factors and scores; in the case of categorical factors, 
number and percentage distribution were used. 
Due to the non-normality of data (graphically 
checked), the Wilcoxon signed-rank test was used to 
evaluate pre- versus post-first line treatment changes 
among variables of interest, whereas the Mann- 
Whitney U tests was applied to compare MRI tumor 
volume changes after treatment between patients 
with and without increased 18F-DOPA uptake. 
Kaplan-Meier estimates of the cumulative 
probability of OS at 12 months were performed and 
log-rank test was adopted to test differences between 
groups (log-rank test for trend in case of 3 or more 
ordinal groups). T/S was evaluated as a dichotomous 
variable (≤1 and >1) in the Kaplan-Meyer analysis. 
The Cox proportional hazard model was used to 
estimate the risk of death from any cause after 
adjustment for age and sex. Only the covariates that 
were significant at the p < 0.05 level in the univariate 
analysis (where we examined all risk factors included 
in our study), were entered into the multivariate 
analysis. The proportional hazard assumption was 
graphically checked. Since the parameters were 
highly correlated, to avoid collinearity, we used 
different models for each parameter to test their 
independent association with OS. We adopted 
1/Variance Inflation Factor (VIF) as a measure of 
collinearity. Two-tailed probabilities were reported, 
and a p value of 0.05 was used to define nominal 
statistical significance; given the explorative nature of 
the study, no multiple testing corrections were 
applied. All analyses were conducted using Stata 
(version 13, Stata-Corp) software. 
Results 
Diagnostic evaluation and correlation with 
tumor response 
Demographic data, histological and molecular 
diagnosis, MRI findings (ring enhancement, pre- and 
post-treatment MRI tumor volumes), 18F-DOPA 
uptake avidity and extent (PET tumor volume and 
uniformity), and survival of all patients are 
summarized in Table 1. A detailed report of all 
patients is provided in Table S1. 
 
Table 1. Summary of patient characteristics, imaging findings and 
survival 
Patient characteristics and 
imaging findings 
n (%) Median (range) 
Gender   
Male 7 (37%)  
Female 12 (63%)  
Age at diagnosis (years)   
<5 3 (16%) 7 (3-10) 
5-8 12 (63%) 
>8 4 (21%) 
Histological and molecular data  
DA, H3K27M-wt 1 (5%)  
AA, H3K27M-wt 1 (5%)  
AA, H3K27M-m 4 (21%)  
GB, H3K27M-m 4 (21%)  
ND 9 (48%)  
Ring enhancement   
Y 6 (31.6%)  
N 13 (68.4%)  
18-F-DOPA uptake patterns   
T/N≤1 4 (21%) T/S 0.44 (0.24-0.55) 
T/N>1-T/S≤1 2 (10.5%) T/S 0.81 (0.70-0.93) 
T/S >1 13 (68.5%) T/S 1.27 (1.06-2.32) 
Imaging findings and OS according to PET semi-quantification 
Pre-treatment MRI tumor volume (cc) 27.64 (18.58-55.63) 
T/N≤1 39.51 (31.46-55.63) 
T/N>1-T/S≤1 25.04 (25.03-25.06) 
T/S >1 27.21 (18.58-46.35) 
Post-treatment MRI tumor volume (cc) 20 (7-42) 
T/N≤1 13.77 (7-20.54) 
T/N>1-T/S≤1 9.81 (8.35-11.27) 
T/S >1 22 (11.18-42) 
Pre-treatment PET tumor volume (cc) 17.2 (0.86-31) 
T/N≤1 No increased uptake 
T/N>1-T/S≤1 6 (4-8) 
T/S >1 18 (0.86-31) 
Pre-treatment PET uniformity (%) 52.5 (3.94-92.57) 
T/N≤1 No increased uptake 
T/N>1-T/S≤1 23.96% (15.96-31.96%) 
T/S >1 62.56% (3.94-92.57%) 
Overall survival (months)  10 (5-38) 
T/S≤1 23 (16-38) 
T/S >1 9 (5-12) 
DA: diffuse astrocytoma, AA: anaplastic astrocytoma, GB: glioblastoma, wt: 
wildtype, m: mutant, ND: not done, Y: yes, N: no. 
 
 
On baseline MRI, areas of ring-shaped 
enhancement were present in 6 DIPGs (31.6%). Three 
of these lesions were glioblastomas, H3K27M-mutant. 
The remaining 5 patients with H3K27M-mutant and 
the 2 patients with H3K27M wild-type DIPGs did not 
show areas of ring enhancement. 
On 18F-DOPA PET imaging, 4 tumors (21%) 
showed absence of increased tracer uptake. Of these, 
two underwent biopsy and turned out to be H3K27M 
wild-type. Two DIPGs presented mildly/moderately 
increased tracer uptake (10.5%), whereas the 
remaining 13 lesions (68.5%) exhibited markedly 
increased uptake. All subjects with H3K27M-mutant 
DIPGs presented markedly increased tracer uptake 





(median T/S ratio: 1.49, range: 1.10-2.32). All subjects 
with ring-shaped enhancement on post-contrast 
T1-weighted images presented also markedly 
increased uptake. In detail, all areas of ring-shaped 
enhancement corresponded to regions with markedly 
increase uptake; however, markedly increase uptake 
extended beyond these areas in 5 out of 6 subjects. 
No lesions presented 18F-DOPA PET tumor 
volumes larger than MRI defined tumor volumes or 
uptake extending beyond MRI defined tumor 
margins. 
Following first line ChT-RT, MRI tumor volumes 
at maximum response were lower than pre-treatment 
tumor volumes (median 20 cc vs 27.64 cc, p < 0.001). 
Patients with absence of increased tracer uptake 
and the 2 patients with mildly/moderately increase 
uptake (T/S ≤ 1) demonstrated higher median degree 
of MRI tumor volume reduction compared to subjects 
with markedly increased tracer uptake (T/S >1) (23.5 
cc versus 5.52 cc; p = 0.001). 
When evaluating the association between 18F- 
DOPA uptake tumor volume at admission with the 
MRI tumor volume at maximum response, areas of 
increased tracer uptake corresponded to regions with 
more prominent residual components/lack of 
response following treatment in all patients. 
Representative images of DIPGs at admission and 
following first-line ChT-RT are reported in Figures 1 
and 2. 
Prognostic evaluation 
The median OS of the whole cohort was 10 
months (range 5-38 months) and cumulative 
probability of survival (OS) at 12 months was 32% 
(95% confidence interval [CI]: 13% - 52%). 
 
 
Figure 1. Co-registered and fused MRI and 18F-DOPA PET images of DIPGs with T/S ≤ 1. First row: 8-year-old male. Pre-treatment contrast-enhanced (CE) 
T1-weighted imaging did not show contrast enhancement. MRI tumor volume (as delineated on FLAIR images) was 31.46 cc. 18F-DOPA PET and fused 18F-DOPA PET/MRI 
revealed absence of increased tracer uptake within the lesion (T/S 0.44). Post-treatment FLAIR at maximum response demonstrated an MRI tumor volume of 7 cc. Overall 
survival (OS) was 27 months. Second row: 7-year-old male (diffuse astrocytoma, H3K27M wild-type). Pre-treatment CE T1-weighted imaging did not reveal areas of contrast 
enhancement. MRI tumor volume was 45 cc. 18F-DOPA PET and fused 18F-DOPA PET/MRI revealed absence of increased tracer uptake (T/S 0.45). On post-treatment FLAIR the 
MRI tumor volume was 16 cc. OS was 38 months. Third row: 7-year-old female. Pre-treatment CE T1-weighted imaging showed lack of contrast enhancement. MRI tumor 
volume was 25.06 cc. PET images revealed absence of increased tracer uptake in the vast majority of the lesion with small areas of mildly-moderately increased uptake (T/S 0.7). 
PET tumor volume was 4 cc, corresponding to a uniformity of 15.96%. Post-treatment FLAIR showed an MRI tumor volume of 8.35 cc. Notice the degree of overlap between 
more prominent residual components on FLAIR and increased 18F-DOPA uptake. OS was 16 months. Fourth row: 5-year-old female. Pre-treatment CE T1-weighted imaging did 
not show contrast enhancement. MRI tumor volume was 25.03 cc. 18F-DOPA PET and fused 18F-DOPA PET/MRI revealed mildly-moderately increased uptake (T/S 0.93) within 
the left ventrolateral component of the lesion (PET tumor volume: 8 cc, uniformity: 31.96%) corresponding to the most prominent residual component following treatment. 
Post-treatment FLAIR demonstrated an MRI tumor volume of 11.27 cc. OS was 28 months. 






Figure 2. Co-registered and fused MRI and 18F-DOPA PET images of DIPGs with T/S > 1. First row: 4-year-old female. Pre-treatment contrast-enhanced (CE) 
T1-weighted imaging showed ring enhancement. MRI tumor volume was 40 cc. 18F-DOPA PET and fused 18F-DOPA PET/MRI revealed markedly increased uptake (T/S 1.09) with 
a PET tumor volume of 21 cc, corresponding to a uniformity of 52.5%. Post-treatment FLAIR demonstrated an MRI tumor volume of 28.9 cc. Overall survival (OS) was 9 months. 
Notice the coincidence between the tumoral component with increased uptake and the residual lesion, and the tumor volume reduction in the left ventrolateral pons 
corresponding to absence of increased uptake. Second row: 7-year-old male (anaplastic astrocytoma, H3K27M-mutant). Pre-treatment CE T1-weighted imaging did not reveal 
areas of ring enhancement. MRI tumor volume was 34.06 cc. On 18F-DOPA PET and fused 18F-DOPA PET/MRI the T/S was 1.27, the tumor volume 25 cc, and the uniformity 
73.39%. Following treatment, the MRI tumor volume was of 33.7 cc. OS was 10 months. Third row: 10-year-old female. On pre-treatment CE T1-weighted imaging there was 
extensive ring enhancement. MRI tumor volume was 26 cc. On 18F-DOPA PET and fused 18F-DOPA PET/MRI the lesion presented a T/S of 1.7 and a tumor volume of 18 cc, 
corresponding to a uniformity of 69.23%. Post-treatment FLAIR image demonstrated an MRI tumor volume of 20 cc. OS was 6 months. Fourth row: 10-year-old male 
(glioblastoma, H3K27M-mutant). Pre-treatment CE T1-weighted imaging revealed a right focal area of ring enhancement. MRI tumor volume was 46 cc. 18F-DOPA PET and fused 
18F-DOPA PET/MRI demonstrated markedly increased uptake (T/S 2.32) and a tumor volume of 31 cc, corresponding to a uniformity of 67.39%. Following treatment, the MRI 
tumor volume was 42 cc. OS was 6 months. 
 
Figure 3 shows Kaplan-Meier OS curves for all 
the main risk factors analyzed in our study. Subjects 
with T/S ratios > 1 (markedly increased uptake) had a 
significantly higher risk of death (p = 0.0001, Figure 
3A) than those with T/S ≤ 1. At the same time, we 
found that at univariate level, H3K27M-mutant 
lesions and patients with ring enhancement on 
post-contrast T1-weighted images had a significantly 
lower survival (hazard ratio [HR] = 3.51, 95% CI: 
1.11-11.1, p = 0.024, not shown, and HR = 3.91, 95% CI: 
1.17-13.1, p = 0.011, Figure 3B). Patients with larger 
MRI tumor volumes at admission did not show lower 
survival (p = 0.738, Figure 3C). By contrast, post- 
treatment MRI tumor volume at maximum response 
and tumor volume reduction following treatment 
were significantly correlated with OS (p = 0.012, 
Figure 3D, and p = 0.005, Figure 3E). Median age and 
gender were not correlated with OS (p = 0.608, not 
shown), whereas patients with greater 18F-DOPA PET 
tumor volume (> 21 cc vs. < 7 cc: HR = 5.74, 95% CI: 
1.46-22.62; 7-21 cc vs. < 7 cc: HR = 2.31, 95% CI: 
0.73-7.34, p = 0.004, Figure 3F) and uniformity (p = 
0.001, not shown) were at higher risk of death. 
However, when we adjusted risk estimates for age 
and gender by using a multivariate Cox model, 
including only the covariates with a significant 
association on univariate analysis, only T/S (HR = 
55.50, 95% CI: 5.3-580.3, p = 0.001), ring enhancement 
(HR 12.4, 95% CI: 1.8-83.1, p = 0.01) and MRI tumor 
volume reduction following treatment (HR 0.1, 95% 
CI: 0.02-0.56, p = 0.01) resulted to be significant 
predictors of OS. A trend emerged for age (p = 0.061) 
(Table 2). 






Figure 3. Kaplan-Meier plots of overall survival (OS) according to T/S (A), ring enhancement (B), pre-treatment MRI tumor volume (C), post-treatment MRI tumor volume at 
maximum response (D), degree of MRI tumor volume reduction (E), and pre-treatment 18F-DOPA PET tumor volume (F). 18F-DOPA PET and MRI (based on FLAIR images) 
tumor volume measurements were categorized considering tertiles of each distribution. 
 
Table 2. Cox regression multivariate analyses (subjects n=19) 
Endpoint Parameter HR* 95% CI p 
OS T/S    
 ≤ 1 1.0 5.3-580.3 0.001 
 > 1 55.5 
 Ring enhancement    
 N 1.0 1.8-83.1 0.01 
 Y 12.4 
 Tumor volume reduction    
 ≤ 11.1 (median) 1.0 0.02-0.56 0.01 
  > 11.1  0.1 
 Age 0.7 0.5-1.0 0.061 
*Hazard ratios (HR) are adjusted for age and sex; 
95% CI: 95% confidence interval, OS: overall survival. 
1/VIF (tolerance): T/S = 0.794; 
Ring enhancement = 0.808; Tum. vol. red. = 0.762; age = 0.834. 
 
Discussion 
The aim of this study was to evaluate and 
correlate 18F-DOPA uptake intensity and extent (PET 
tumor volume and uniformity) with conventional 
MRI indices, and with treatment response and 
survival of pediatric patients with DIPGs. To the best 
of our knowledge, no prior studies have so far 
evaluated the role of 18F-DOPA PET on a selected 
population of children with DIPGs. Overall, a limited 
number of studies have assessed PET imaging in 
DIPGs [21,22,24-27]. 
Zukotynski et al. [21] analyzed the role of 
18F-fluorodeoxyglucose (FDG) PET in patients with 
newly diagnosed DIPGs and observed that the 
intensity of FDG uptake did not correlate with 
outcome; however, in patients with 18F-FDG PET 
uptake involving more than half of the tumor, 
survival appeared to be decreased. A more recent 
study from the same group [24] evaluated 18F-FDG 
histogram metrics in children with DIPGs, revealing 
that parameters such as skewness or kurtosis did not 
show a significant association with outcome. 
An additional multimodal study with 18F-FDG 
PET performed by Goda et al. [25] did not find a 
significant correlation between baseline DIPGs 
18F-FDG uptake and survival, even though patients 
with increased PET uptake had a lower 1-year OS 
(40%) and PFS (33%) compared to patients with lower 
uptake (66.7% and 40%, respectively). 
Of note, among amino-acid PET tracers, only 
three prior pediatric research studies, all performed 
with 11C-Methionine (MET), have been performed 
[22,26,27]. Two of these studies evaluated both 18F- 
FDG and 11C-MET to characterize the tumoral 
metabolic activity. In particular, Pirotte et al. [26] 
investigated a group of children with different 
infiltrating brainstem tumors highlighting the role of 
PET imaging to biopsy planning and target selection. 
Rosenfeld et al. [27], a few years later, found that 
patients with the shortest survival time were those 
who had 18F-FDG negative and 11C-MET positive 
scans, whereas patients with the longest survival 
times were those with both negative 18F-FDG and 
11C-MET scans suggesting a trend toward improved 
survival, even though the correlation was not 
statistically significant. 
A very recent study performed by Tinkle et al. 
[22] evaluated the role of 11C-MET PET in 22 subjects 
with typical and atypical DIPGs, treated with RT 
using conventional fractionation (1.8Gy per day) to a 





total dose of 54‐55.8Gy; although baseline 11C-MET 
PET intensity and uniformity metrics did not correlate 
with survival outcomes, initial 11C-MET avidity 
overlapped with recurrent tumor in 100% of cases, 
delineating regions at increased risk for recurrence. 
These authors also suggested to explore the role of 
18F-DOPA in this pediatric tumor subtype. 
In the present study, a significant relationship 
between 18F-DOPA uptake avidity and extent 
(18F-DOPA tumor volume and uniformity) was found 
in terms of OS on univariate analysis, and the 
18F-DOPA PET metric T/S was an independent 
predictor of survival on multivariate analysis. Of note, 
all DIPGs with a T/S ratio >1 (markedly increase 
tracer uptake) presented an OS ≤ 12 months. As 
demonstrated in prior studies [16-18,23], T/S ratio is 
an extremely helpful 18F-DOPA PET parameter to 
predict pediatric diffuse astrocytic tumor behavior in 
a clinical diagnostic setting; moreover, 18F-DOPA 
uptake in the striatum allows to further stratify tumor 
uptake ratios when compared to other amino-acid 
PET tracers. Of note, even though striatal 18F-DOPA 
uptake may be subject to changes related to age in 
adults [28,29], we believe that in our pediatric 
population (children aged 3 to 10 years) the impact of 
age-related striatal uptake does not appear to be 
significant. 
As previously reported in a large DIPG study [4], 
also in our current research the presence of ring 
enhancement on MRI proved to be an additional 
independent predictor of adverse OS. Of note, when 
considering our population, only 6 DIPGs presented 
this MRI finding while, among the remaining 13 
subjects without ring enhancement, 7 additional 
patients presented an OS ≤ 12 months. Overall, among 
subjects with an OS ≤ 12 months, 46% presented ring 
enhancement whereas 100% presented a T/S ratio >1. 
Regarding the relationship between 18F-DOPA 
accumulation and areas of contrast-enhancement, in 
all but one subjects markedly increase uptake 
extended beyond these areas, and was present in 
additional seven subjects without any area of 
contrast-enhancement, thus providing additional 
non-invasive diagnostic information in keeping with 
prior studies [15,16,30]. 
Tumor volume reduction following therapy 
(difference between MRI tumor volume at admission 
and at maximum response following first line 
treatment) also correlated significantly with OS on 
multivariate analysis. This result is in line with a prior 
study demonstrating that patients with more 
substantial tumor volume decrease following therapy 
had better OS [20]. Differently from the above- 
mentioned study, MRI tumor volume at admission 
did not show a significant correlation with outcome. 
When compared to MRI tumor volume decrease, 
the main potential advantage of 18F-DOPA PET T/S 
ratio or presence of ring enhancement consists in the 
possibility of obtaining prognostic information at 
admission and not following treatment. 
When compared to the amino-acid PET tracer 
11C-MET, which did not show a correlation between 
uptake and outcome [22], our findings suggest that in 
DIPGs 18F-DOPA uptake might be related to 
additional mechanisms, such as expression of 
supplementary amino-acid transporters, as 
demonstrated in a prior study where 18F-DOPA 
uptake values of brain gliomas were not exclusively 
dependent on L-type amino-acid transporter (LAT) 1 
expression [31,32]. In adult diffuse gliomas has been 
suggested that an apparent discrepancy between the 
uptake patterns of 11C-MET and 18F-DOPA may be 
linked to the metabolomic profile of IDH-mutated 
tumors [33]. Since pediatric diffusely infiltrating 
astrocytic tumors typically do not present IDH 
mutation different mechanisms should be considered. 
In a current ongoing unpublished research, our 
preliminary findings show that the glutamine 
transporter sodium-coupled neutral amino-acid 
transporter (SNAT) 1 (Slc38a1) is involved in 
18F-DOPA uptake of cell lines of pediatric high-grade 
gliomas, in addition to LAT1. Further studies are 
needed to evaluate and elucidate the potential role of 
glutamine for DIPGs survival and proliferation. 
Glutamine addiction in adult high-grade gliomas is 
well known [34]. 
In a recent study we also demonstrated that 
anaplastic astrocytomas and glioblastomas H3K27M- 
mutant arising in midline brain structures had a 
significant higher uptake than wild-type midline 
high-grade gliomas [18]. H3K27M-mutant diffuse 
midline gliomas, which include about 85% of DIPGs, 
have been reported to exhibit elevated expression and 
dependency on dopamine receptor (DR) D2 [35]. 
DRD2 is a G protein-coupled receptor that promotes 
tumor growth. A recent study also demonstrated that 
glioblastoma cells (including tumor samples from 
patients) can synthesize and secrete dopamine, 
suggesting an autocrine signaling process and an 
underlying role for dopamine in gliomagenesis [36]. 
DOPA is a precursor for dopamine synthesis, and 
when compared to other amino-acid PET tracers 
18F-DOPA uptake might be more specifically related 
to cells that synthesize and secrete dopamine. 
In the study performed by Tinkle et al. [22] 
11C-MET PET-delineated tumor extended beyond the 
T2-FLAIR abnormality in most patients at diagnosis. 
This is in distinction to our findings where 18F-DOPA 
PET-delineated tumor was always confined within 
the MRI tumor volume. However, when comparing 





the association between pre-treatment 18F-DOPA PET 
tumor volume and post-treatment MRI tumor 
volume, areas of increased 18F-DOPA uptake 
corresponded to regions with more prominent 
residual components/lack of response in all patients. 
This finding is in line with the above-mentioned study 
[22] demonstrating a correlation between the location 
of increased 11C-MET uptake at admission and the 
subsequent region of local tumor progression. 
Considering the significant association between 
18F-DOPA uptake avidity and extent with outcome, 
our findings indicate that tumoral areas with 
increased tracer uptake show a more aggressive 
biological behavior, with reduced sensitivity to 
ChT-RT. 
In the era of precision medicine, the results of the 
present study could delineate subcategories of 
patients who might benefit from personalized 
management strategies. 
Given the lack of current medical therapies able 
to significantly impact outcome and the known 
feasibility of re-irradiation for recurrent DIPGs 
[37,38], a more personalized RT treatment might be 
tested on the basis of the metabolic characteristics of 
the lesion; such an approach might also be considered 
as selection criteria in discriminating DIPGs that may 
better benefit re-irradiation, since not all DIPGs 
improve prognosis with re-RT, as reported in a recent 
meta-analysis [37]. 
In addition, patients with lack of increased 18F‐
DOPA uptake or with mild-moderate uptake (which 
correlate with higher tumor volume response degree 
and better outcome) might be selected to perform a 
first radiotherapy course with lower dose than 54 Gy 
at admission, in order to give them the possibility of 
multiple radiotherapy courses. A current clinical trial 
(NCT03620032; clinicaltrials.gov) is actively 
investigating multiple elective RT courses in DIPGs. 
The role of 18F-DOPA PET might also be 
evaluated on follow-up studies to assess treatment 
response. A prior study performed in adult patients 
with recurrent high-grade malignant gliomas on 
antiangiogenic treatment demonstrated the powerful 
role of 18F-DOPA PET in assessing treatment response 
and for providing prognostic information [39]. 
Our results should be interpreted with 
awareness of some limitations. This is a retrospective 
study in which a limited number of patients was 
evaluated; however, we included only pediatric 
patients with DIPGs studied with 18F-DOPA PET, and 
currently our cohort constitutes to the best of our 
knowledge the first and largest series of DIPGs 
evaluated with this technique so far. We acknowledge 
that only 10 out of 19 subjects underwent biopsy, thus 
limiting the molecular characterization of the entire 
cohort. However, the aim of the present study was to 
evaluate the degree of correlation between 18F-DOPA 
PET avidity and extent with outcome, and molecular 
characterization of DIPG did not influence the 
treatment regimen which was homogeneous among 
subjects. In the current study we evaluated only static 
18F-DOPA PET parameters; as highlighted in a recent 
research on adult gliomas [40], dynamic 18F-DOPA 
PET analysis in pediatric gliomas might provide 
additional information in future investigations. 
Furthermore, in this study we did not compare 
18F-DOPA PET with advanced MR imaging 
modalities; as highlighted in a recent study which 
demonstrated a significant association of different 
advanced MR imaging metrics with survival [41], 
prospective clinical trials should be performed in 
order to evaluate the synergic role of these techniques. 
We recognize that in the current study we did not 
evaluate the prognostic role of T/N, even though we 
used this parameter to stratify tumor uptake patterns 
and to delineate tumor volume. However, in pediatric 
diffusely infiltrating astrocytic tumors, according to 
our experience, the T/N ratio did not provide 
additional information when compared to T/S, in 
terms of differentiation between low-grade and 
high-grade lesions and with regard to outcome 
prediction [17,23]; of note, in pediatric diffuse midline 
gliomas, which according to the revised 2016 World 
Health Organization classification of tumors of the 
central nervous system include DIPGs, T/S was the 
only parameter able to discriminate H3K27M-mutant 
from wild-type tumors, independently of histology 
[18]. Furthermore, as reported by the Joint 
EANM/EANO/RANO practice guidelines/SNMMI 
procedure standards for imaging of gliomas using 
PET with radiolabelled amino-acids [42], the striatum 
is the only recommended reference region for 
semiquantitative measures of 18F-DOPA PET activity. 
However, regarding cut-off thresholds for definition 
of biological tumor volume the EANM/RANO/ 
EANO and SNMMI guidelines indicate for 18F-DOPA 
a standardized uptake value (SUV) higher than the 
mean SUV in healthy striatum [39,42]. Since it is 
acknowledged that this cut-off value lacks histological 
validation [42], and according to Cicone et al. [43], we 
used a different threshold. Of note, since when 
compared to their adult counterparts, pediatric 
astrocytic tumors are considered biologically distinct 
entities [44], and in light of the complex physiological 
changes occurring in the brain during development, 
especially in the first two years of life (i.e., cortical 
organization, white matter myelination, changes in 
cerebral blood flow), current adults guidelines and 
18F-DOPA PET literature based on adult gliomas may 





not be entirely applicable to pediatric gliomas, 
especially in the era of precision medicine. 
Conclusions 
18F-DOPA PET imaging provides useful non- 
invasive information for evaluating the metabolism of 
DIPGs. Our results demonstrate that the 18F-DOPA 
PET metric T/S is an independent predictor of overall 
survival. 18F-DOPA uptake extent corresponds to 
tumoral components with a more aggressive 
biological behaviour, less sensitive to first line 
ChT-RT. Larger prospective studies are needed to 
evaluate whether 18F-DOPA PET can provide 
additional information for more personalized 
management schemes. 
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